Study guide

10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

Key Takeaways Explain This Topic AI

Sodium-glucose co-transporter 2 (SGLT2) inhibitors can cause euglycaemic diabetic ketoacidosis; UK guidance omits them on the day before and the day of surgery, while US labelling advises stopping 3 days before (4 days for ertugliflozin).

Non-selective monoamine oxidase inhibitors interact dangerously with pethidine, tramadol, dextromethorphan and methadone (serotonin syndrome) and with indirectly acting sympathomimetics such as ephedrine (hypertensive crisis).

Lithium has a narrow therapeutic range (about 0.4-1.0 mmol/L), prolongs neuromuscular blockade, and its levels rise with dehydration, NSAIDs, ACE inhibitors and thiazide diuretics.

Enzyme-inducing antiepileptics such as carbamazepine and phenytoin increase requirements for non-depolarising neuromuscular blockers and opioids and accelerate the metabolism of many drugs.

Antiparkinsonian drugs should be continued perioperatively because omission can precipitate rigidity and a neuroleptic malignant-like syndrome, and dopamine antagonists such as metoclopramide and haloperidol should be avoided.

Last updated: October 2026

10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

Why These Drugs Matter

EDAIC Paper A tests the pharmacology of drugs used in internal medicine, and Paper B tests their perioperative management. Most interactions follow a few principles: enzyme induction or inhibition, additive effects on the central nervous system or QT interval, and drugs that alter catecholamine or serotonin handling.

Drugs for Diabetes

Class Examples Mechanism Perioperative points

Biguanide Metformin Reduces hepatic glucose output, improves insulin sensitivity Low hypoglycaemia risk; omit if contrast or acute kidney injury risk, or on the day of surgery when a meal is missed (local protocols vary)

Sulphonylureas Gliclazide, glibenclamide Close beta-cell ATP-sensitive potassium channels, releasing insulin Hypoglycaemia risk; omit on the morning of surgery

SGLT2 inhibitors Dapagliflozin, empagliflozin Glycosuria by blocking renal glucose reabsorption Euglycaemic ketoacidosis ; omit the day before and the day of surgery; check ketones if unwell

DPP-4 inhibitors Sitagliptin Prolong incretin action Low risk; may continue

GLP-1 receptor agonists Semaglutide, liraglutide, tirzepatide (dual) Increase insulin secretion, slow gastric emptying Delayed gastric emptying and aspiration risk; follow current society guidance on withholding and consider gastric ultrasound or rapid sequence induction

Insulin Basal and bolus regimens Replacement Continue long-acting basal insulin at about 80% of the usual dose; use a variable-rate infusion for long fasting

Thyroid Drugs

Levothyroxine: half-life about 7 days, so a missed dose on the day of surgery is harmless.

Carbimazole and propylthiouracil (PTU) inhibit thyroid peroxidase. PTU also inhibits peripheral conversion of T4 to T3 and is preferred in the first trimester of pregnancy and thyroid storm. Agranulocytosis is a rare serious adverse effect of both.

Beta-blockers (propranolol) control adrenergic symptoms and reduce peripheral T4-to-T3 conversion.

Iodine (Lugol's solution) acutely inhibits hormone release (Wolff-Chaikoff effect) and reduces gland vascularity before thyroidectomy.

Corticosteroids

  • Steroid Relative glucocorticoid potency Relative mineralocorticoid potency Equivalent dose
  • Hydrocortisone 1 1 20 mg
  • Prednisolone 4 0.8 5 mg
  • Methylprednisolone 5 Minimal 4 mg
  • Dexamethasone 25-30 Negligible 0.75 mg
  • Fludrocortisone 10 125-250 Used for mineralocorticoid replacement

Patients on long-term steroids need perioperative cover, typically hydrocortisone 100 mg at induction followed by an infusion or regular doses for major surgery.

Respiratory Drugs

Beta-2 agonists (salbutamol, salmeterol): bronchodilation through cyclic AMP; cause tachycardia, hypokalaemia and lactic acidosis at high doses.

Antimuscarinics (ipratropium, tiotropium): block M3 receptors on airway smooth muscle.

Inhaled corticosteroids: reduce airway inflammation; high doses can suppress the adrenal axis.

Theophylline and aminophylline: non-selective phosphodiesterase inhibition and adenosine antagonism. Narrow therapeutic range (10-20 mg/L); toxicity causes arrhythmias and seizures. Levels rise with enzyme inhibitors (erythromycin, ciprofloxacin) and fall with smoking and inducers.

Leukotriene receptor antagonists (montelukast): continue perioperatively.

Magnesium sulphate (2 g IV over 20 minutes) is used in acute severe asthma.

  • Antidepressants and Psychiatric Drugs
  • Selective Serotonin Reuptake Inhibitors (SSRIs)

Usually continued. They increase the risk of serotonin syndrome with tramadol, pethidine, fentanyl (rarely), ondansetron combinations, methylene blue and linezolid. They impair platelet serotonin uptake, slightly increasing bleeding, and can cause hyponatraemia (SIADH).

Tricyclic Antidepressants (TCAs)

Block noradrenaline and serotonin reuptake and have antimuscarinic, antihistaminic and alpha-1 blocking effects. They prolong the QT interval and increase sensitivity to directly acting catecholamines; give vasopressors in reduced doses. Overdose causes sodium channel blockade with a wide QRS (treated with sodium bicarbonate).

Monoamine Oxidase Inhibitors (MAOIs)

Interaction Mechanism Result

Pethidine, tramadol, dextromethorphan, methadone Serotonin reuptake inhibition Serotonin syndrome (hyperthermia, clonus, agitation, autonomic instability)

Indirect sympathomimetics (ephedrine, metaraminol) Release of accumulated noradrenaline Severe hypertensive crisis

Tyramine-rich foods Unmetabolised tyramine releases noradrenaline Hypertensive crisis

Directly acting vasopressors (phenylephrine, noradrenaline) in small titrated doses are safer. Irreversible MAOIs used to be stopped 2 weeks before surgery, but current practice is usually to continue them and avoid interacting drugs, after discussion with the psychiatrist. Moclobemide is reversible and short-acting.

Lithium

Narrow therapeutic range (about 0.4-1.0 mmol/L ); toxicity above about 1.5 mmol/L causes tremor, confusion, seizures and arrhythmias.

Renally excreted like sodium: dehydration, NSAIDs, ACE inhibitors and thiazides raise levels.

Prolongs neuromuscular blockade and may reduce anaesthetic requirements; causes nephrogenic diabetes insipidus and hypothyroidism.

Usually continued for minor surgery with levels checked; often withheld 24 hours before major surgery and restarted when renal function and fluid balance are stable.

Antipsychotics

Dopamine D2 antagonists (haloperidol, olanzapine, quetiapine) cause sedation, hypotension (alpha-1 block), QT prolongation, extrapyramidal effects and, rarely, neuroleptic malignant syndrome (hyperthermia, rigidity, raised creatine kinase, autonomic instability), treated with cooling, dantrolene and bromocriptine.

Antiepileptic Drugs

Drug Mechanism Anaesthetic interaction

Phenytoin Sodium channel blockade Enzyme inducer; chronic use causes resistance to non-depolarising NMBDs; zero-order kinetics at therapeutic levels

Carbamazepine Sodium channel blockade Strong enzyme inducer; resistance to NMBDs and opioids; hyponatraemia

Sodium valproate Several mechanisms Enzyme inhibitor; thrombocytopenia and platelet dysfunction; hepatotoxicity

  • Levetiracetam Binds synaptic vesicle protein SV2A Few interactions; available intravenously
  • Lamotrigine Sodium channel blockade Few anaesthetic interactions

All antiepileptics should be continued perioperatively, using intravenous forms when the enteral route is unavailable. Missed doses risk breakthrough seizures.

Drugs for Parkinson's Disease

Levodopa (with a decarboxylase inhibitor) has a short half-life; missing even a few hours of doses can cause severe rigidity, dysphagia and respiratory compromise. Give the usual doses up to and immediately after surgery, use a nasogastric tube if needed, or switch to a rotigotine skin patch. Avoid metoclopramide, prochlorperazine and haloperidol ; use domperidone or ondansetron for nausea. Selegiline and rasagiline are MAO-B inhibitors and interact with pethidine.

Enzyme Induction and Inhibition

Inducers (reduce effect of other drugs) Inhibitors (increase effect of other drugs)

Rifampicin, carbamazepine, phenytoin, phenobarbital, St John's wort, chronic alcohol, smoking (CYP1A2) Amiodarone, macrolides (clarithromycin, erythromycin), azole antifungals, ciprofloxacin, grapefruit juice, ritonavir, cimetidine, acute alcohol

CYP3A4 inhibitors such as clarithromycin, diltiazem or ritonavir can markedly prolong the effects of midazolam, fentanyl and alfentanil.